RE:RE:RE:RE:Why i am not accumulatingGoaweigh wrote: I've been following ATE for quite awhile now, owed it , sold it, bought it all back and more just recently but I've never heard any mention of Covid or Alzheimers or Parkinsons, where does this come from ?
Thanks
MrMugsy wrote: Beanie28 wrote:
go away
Ya - I've heard it all before.
No one knows which way this goes but the odds are on it going up in the near-term.
Cash in the bank means we are in a stronger position - for negotiating and as a company.
If I'm an institutional investor and I look at this balance sheet ... much stronger now.
Keep the exciting news flowing (still lots availabe) and we're making our way to a US exchange.
Remember ... keep the list in mind ...
1. P3 design updates (including all pre-P3 animal study results)
2. FDA meeting
3. -352 updates
4. -340 updates (could be related to a COvID update as well)
5. fast iteration drug development updates (betting on an Alzheimer's/Parkinsons or a brain cell drug carrier next)
6. US exchange
7. amagamation
8. collaborations (heck ... if drug development is going to improve ... might as well find partners to help push some of these new drugs to the finish line faster - some with lots of cash - that collaboration could end up being a take-out partner one day.
9. partnerships
10. sale of Citagenix
11. all the others I missed on this list
So many possible angles and I wouldn't bet that we stand still ... not with cash in the bank and a technical advantage in "fast iterations" for gaseous mediator development. Kings of a whole new field of medicine ???????
Cheers All !
Other opportunities for H2S have been listed on ATE's corporate presentations in the past. Sometines added and sometimes removed. Just as their old IBD drugs have been listed there in the past and removed (ATB-428 and ATB-429).
Things change quickly here so you may not see those drugs or other future opportunities listed anymore.
Keep in mind that Dan also mentioned something very important in a National Post aricle (a few months back) ...
“We’re going to initiate a whole new field around what are called the gaseous mediators: nitric oxide, hydrogen sulfide, and carbon monoxide,” Dan Legault, CEO of Antibe Therapeutics, said by phone this month. Anyway ... you also need to look at the articles Dan posts on LinkedIN and Facebook and you quickly realize that an article about how H2S can help Central Sleep Apnea ... to help your lungs keep breathing ... all relates to brain function and improved cell communication. H2S is also about slowing down the aging process and keeping cells vibrant. This all relates back to past lists of opportunities Dan had in ATE's presentations.
Now that we know our academic studies are aligned with fast iteration abilitly and the ability to measure H2S at the cell level, they can play with the carrier molecules and see which are optimal for which purposes (I believe).
This all relates well to building the value of this company as this is the critical time to be developing new drugs - providing more value for partners.
So, keep in mind that my comments are nothing more than guesses (as I mentioned) but they relate to facts about what the company considers important, what they potentially can do now (with their academic partner) and where the value just might be.
That's all. Hope that helps.